

For Immediate Release
May 1, 2006

Contact: Mathias Neuman
(240) 477-1211

**BioDerm Sciences, Inc. Reports Remarkable
Findings in Wound Care**
Dramatic Improvements May Lead to Reduced Health Care Costs

Oxford, MS – BioDerm Sciences, Inc. a pharmaceutical and medical device company created to accelerate wound healing, is presenting results of two important wound care studies this week. The groundbreaking results of the studies will be unveiled during two presentations at the 2006 Symposium on Advanced Wound Care in San Antonio, Texas on April 30-May 3, 2006.

These significant studies contain findings that could ultimately lead to reduced recovery time and hospital costs. The first study showed that wound care formulations can inhibit and some cases kill bacteria. This could mean the end of the use of antibiotics to prevent rather than treat infection following surgery, a practice that contributes to drug-resistant strains of bacteria. The second study examined a dressing that expedites healing and lessens scarring, which in turn, lessens the need for re-dressing the wound and extended hospital stays.

In the first study, researchers Janni Tsioras, Thomas Riesinger and Ed Gubish, Ph.D., investigated the ability of acidic wound management formulations to effect the growth of various microbiological agents. Spray and cream wound management formulations were evaluated with regard to the ability of organisms to contaminate these formulations and the ability of the acidic formulations to prevent growth of bacteria, yeast and fungi. In all cases, the formulations proved not to support the growth of microorganisms and in fact were bactericidal in some cases.

In the second study, authors Thomas Riesinger and Edward Gubish, Ph.D., describe the efficacy and safety of an innovative moist wound dressing in patients following an extensive surgical procedure for pectus excavatum (funnel chest). Forty male patients were selected at random to receive either a moist wound dressing or a standard dry dressing. The moist wound dressing consisted of a non-woven fabric coated with a nanolayer of metallic silver containing a zinc/iron wound solution. In this study, the BioDerm Sciences Wound System demonstrated dramatic improvement over conventional wound dressing. The patients who received the moist wound dressing experienced decreased time for the wound to heal, elimination of infection, reduced scarring and reduced post-surgical wound care costs.

“We find the results of these studies truly remarkable,” said Edward Gubish, Ph.D., Chief Scientific Officer. “On one hand, in a laboratory setting, to demonstrate anti-microbial activity without an antibiotic present shows a potential to inhibit clinically present antibiotic resistant strains. On the other hand, we have shown that improved wound care in the post-surgical setting can result in decreased infection, decreased post-surgical care, decreased use of prophylactic antibiotics, and ultimately decreased cost of procedures. Both studies demonstrate the dramatic capabilities of the next generation of wound care formulations.”

To view the poster presentation, visit the BioDerm web site at www.bioderm Sciences.com.

###

About BioDerm Sciences Inc.

A pharmaceutical and medical device Delaware C-Corporation created to accelerate wound healing, BioDerm Sciences optimizes a portfolio of nine in-licensed products in the dermatological fields of wound management, sports medicine and first aid. BioDerm Sciences recently launched a series of these dermatological products in Europe and is currently initiating U.S. commercialization. The company has its current headquarters offices at the Enterprise Center, 9 Industrial Park Drive, Oxford, MS 38655 and European operations for its subsidiary, BioDerm Sciences Ltd., at One Earlsfort Centre, Earlsfort Terrace, Dublin 2 Ireland. For more information, go to <http://www.bioderm Sciences.com>.